The U.S. Chamber of Commerce is supporting GlaxoSmithKline’s bid to overturn a court decision allowing the state of Louisiana to bring antitrust claims against the drugmaker even though it did not opt out of a related, previous class action settlement.
The Chamber filed a brief on Tuesday asking the full 3rd U.S. Circuit Court of Appeals in Philadelphia to review a three-judge panel’s decision holding Louisiana’s sovereign immunity meant it was not bound by a deal resolving claims that GSK tried to delay generic versions of its allergy drug Flonase.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2mST6yO
 